Clinical Trial Update: Study Evaluating Prevenar Vaccine in Healthy Infants [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the Prevenar pneumococcal vaccine in healthy infants has been completed; Wyeth is now part of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevenar (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Pneumococcal Infections | Phase 4 | Status: COMPLETED